Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

MHRA approves Brinsupri (brensocatib) targeting dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis treatment
Small molecule, respiratory disease, dipeptidyl peptidase 1 inhibitor, non-cystic fibrosis bronchiectasis - Read more

Immedica Pharma's Loargys (pegzilarginase-nbln) receives FDA accelerated approval for Arginase 1 Deficiency hyperargininemia treatment
Protein therapy, metabolic, enzyme replacement therapy, arginase 1 deficiency, hyperargininemia, pediatric patients - Read more

Bora Pharmaceuticals, GSK renew five-year manufacturing agreement covering 335 products worth $250M
Manufacturing agreement, infectious disease, small molecule, commercial manufacturing - Read more

Fortress Biotech sells FDA priority review voucher for $205M following Zycubo approval
Asset sale, rare disease, regulatory, milestone payments - Read more

Astellas, Vir Biotechnology partner on masked prostate cancer bispecific VIR-5500, $335M upfront, $1.7B total
Licensing deal, oncology, bispecific antibody, milestone payments - Read more

Angelini Pharma, Quiver Bioscience partner on AI-driven genetic epilepsy therapies, $120M milestones
Research collaboration, neurological, AI/ML, rare disease, milestone payments - Read more

Harbour BioMed, Solstice Oncology license anti-CTLA-4 antibody HBM4003, $105M upfront, $1.2B total
Licensing deal, oncology, antibody, milestone payments, equity investment - Read more

Frontier Biotechnologies, GSK license two siRNA products for $40M upfront, $963M milestones
Licensing deal, siRNA, milestone payments, royalties - Read more

Blackstone Life Sciences, Johnson & Johnson co-fund bleximenib clinical trials for acute myeloid leukemia
Co-funding agreement, oncology, small molecule, R&D - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

Vir Biotechnology reports positive Ph1 results for VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer
Protein therapy, cancer, T-cell engager, metastatic castration-resistant prostate cancer, PSMA target - Read more

Protara Therapeutics' TARA-002 shows 68% complete response rate in Ph2 trial for non-muscle invasive bladder cancer
Cell therapy, cancer, intravesical therapy, non-muscle invasive bladder cancer, BCG-unresponsive - Read more

Generate:Biomedicines plans $425M IPO to bankroll antibody's phase 3 asthma trials
Antibody, respiratory disease, AI-driven, CAR-T, clinical-stage - Read more

Apotex seeks $730M IPO, Canadian generic drugmaker going public 2026
Generic drugs, small molecule - Read more

AbbVie invests $380M in two new North Chicago API plants for neuroscience and obesity medications
Small molecule, neurological, strategic, major transaction, operational - Read more

REGENXBIO wins appellate court ruling against Sarepta Therapeutics in gene therapy patent dispute over Elevidys technology
Gene therapy, rare disease, strategic, competitive - Read more

Gilead to acquire CAR T partner Arcellx for $7.8B ahead of potential anito-cel approval
CAR-T, oncology, strategic, major transaction - Read more

Promise Bio launches Frontier Epiproteomic Innovation Grant providing R&D access to epiproteomic analysis for biotech companies
Epiproteomics, immunology, strategic, operational - Read more

FDA publishes draft guidance for personalized genetic medicines targeting rare diseases through Plausible Mechanism Pathway
Gene editing, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Roche halts satralizumab (anti-IL-6 receptor antibody) Ph2 study for Duchenne muscular dystrophy citing no realistic approval path
Antibody, neurological, monoclonal antibody, Duchenne muscular dystrophy, IL-6 receptor target - Read more

Gossamer Bio's seralutinib (PDGFRα/β, CSF1R, c-KIT inhibitor) fails Ph3 trial for pulmonary arterial hypertension treatment
Small molecule, cardiovascular, kinase inhibitor, pulmonary arterial hypertension, inhaled delivery, PDGFR inhibitor - Read more

Novo Nordisk's CagriSema falls short of Eli Lilly's Zepbound in Ph3 obesity head-to-head trial
Small molecule, metabolic, GLP-1 agonist, obesity, combination therapy - Read more

Bayer sues Johnson & Johnson over allegedly false advertising claims promoting Erleada superiority over Nubeqa
Small molecule, oncology, competitive, regulatory - Read more

Bristol Myers Squibb to eliminate 247 New Jersey jobs as part of ongoing $2B restructuring effort
Operational, cost reduction, strategic, financial - Read more

EU pauses US trade deal affecting pharmaceutical tariffs after Supreme Court ruling, Trump threats
Pharmaceuticals, regulatory, strategic, major transaction - Read more

CDC Principal Deputy Director Ralph Abraham steps down amid ongoing leadership shake-up at agency
Infectious disease, regulatory, operational, strategic - Read more

Merck & Co. splits cancer, specialty drug businesses in leadership shakeup preparing for Keytruda patent cliff
Cancer immunotherapy, oncology, strategic, operational, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here